Foshan ACXEL Technology Co., Ltd. announced on Thursday that it has obtained over $10 million in a pre-A+ round of financing. The leading investor was Qiming Venture Partners, while existing shareholders GL Ventures, Country Garden Venture Capital, Cowin Capital and Linear Capital also participated.
Following this funding round, ACXEL is poised to further accelerate its layout and workflow in cell biology, systematic biology and synthetic biology, improve the development and production of supporting chips, devices and reagents, and expand upstream and downstream cooperation.
ACXEL boasts the world’s leading digital microfluidic platform and provides revolutionary technology to address the serious need for high-throughput screening, discovery and functional studies at the individual microbial, cellular and molecular levels.
Leveraging large-scale thin-film active pixel array technology, ACXEL is capable of creating large-scale digital microdroplets containing biological samples in parallel on a two-dimensional plane for real-time detection and profiling. It can also continuously handle droplets of arbitrary interest in parallel. In this way, ACXEL can effectively assist in high-precision research and application development in the life sciences.
ACXEL’s founding team holds distinctive and grounded experience in cutting-edge technological innovation and application in cell biology, and its core members are from prestigious universities and research institutions both in China and abroad, including the University of Cambridge and Peking University.
Regarding the fresh funds, Dr. Ma Hanbin, founder and CEO of the company, said: “We firmly believe the sophisticated semiconductor manufacturing craftsmanship and consumer electronics technology in the Greater Bay Area enables complex life science research to be perfectly materialized on a CPU-like chip, and also strongly believe that the chip, which carries automated and high-precision experimental processes, will become the underlying technology platform for digital biology, or even the infrastructure in life sciences.”